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Reciprocal Regulation of MicroRNA-1 and Insulin-Like
Growth Factor-1 Signal Transduction Cascade in
Cardiac and Skeletal Muscle in Physiological and
Pathological Conditions
Leonardo Elia, PhD; Riccardo Contu, BSc; Manuela Quintavalle, PhD; Francesca Varrone, PhD;
Cristina Chimenti, MD, PhD; Matteo Antonio Russo, MD; Vincenzo Cimino, MD;
Laura De Marinis, MD; Andrea Frustaci, MD; Daniele Catalucci, PhD; Gianluigi Condorelli, MD, PhD
Background—MicroRNAs (miRNAs/miRs) are small conserved RNA molecules of 22 nucleotides that negatively
modulate gene expression primarily through base paring to the 3! untranslated region of target messenger RNAs. The
muscle-specific miR-1 has been implicated in cardiac hypertrophy, heart development, cardiac stem cell differentiation,
and arrhythmias through targeting of regulatory proteins. In this study, we investigated the molecular mechanisms
through which miR-1 intervenes in regulation of muscle cell growth and differentiation.
Methods and Results—On the basis of bioinformatics tools, biochemical assays, and in vivo models, we demonstrate that
(1) insulin-like growth factor-1 (IGF-1) and IGF-1 receptor are targets of miR-1; (2) miR-1 and IGF-1 protein levels are
correlated inversely in models of cardiac hypertrophy and failure as well as in the C2C12 skeletal muscle cell model
of differentiation; (3) the activation state of the IGF-1 signal transduction cascade reciprocally regulates miR-1
expression through the Foxo3a transcription factor; and (4) miR-1 expression correlates inversely with cardiac mass and
thickness in myocardial biopsies of acromegalic patients, in which IGF-1 is overproduced after aberrant synthesis of
growth hormone.
Conclusions—Our results reveal a critical role of miR-1 in mediating the effects of the IGF-1 pathway and demonstrate
a feedback loop between miR-1 expression and the IGF-1 signal transduction cascade. (Circulation. 2009;120:2377-
2385.)
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MicroRNAs (miRNAs/miRs) are small conserved RNAmolecules of"22 nucleotides that negatively modulate
gene expression in eukaryotic organisms. The base pairing of
a specific miR to the 3! untranslated region (UTR) of its
messenger RNA (mRNA) targets leads to mRNA cleavage
and/or translation repression.1 Bioinformatic analysis predicts
that each miR may regulate hundreds of targets, indicating
their important role in most biological processes such as cell
proliferation, apoptosis, and stress responses.2–5 Recently,
these small RNA molecules have also been demonstrated to
be involved in myocardial and cardiac stem cell develop-
ment,6 cardiac hypertrophy and remodeling, and arrhyth-
mias,7–11 as is the case of miR-1,6,12–14 the expression of
which inversely correlates with cardiac hypertrophy.11,15 No-
tably, mice harboring deletion of miR-1 showed cardiac
defects, including misregulation of cardiac morphogenesis,
electric conduction, and cell proliferation.10,14 Among puta-
tive miR-1 targets, proteins such as growth factors (Toll-like),
transcription factors, and signal transduction kinases have
been validated as true targets.12,13
Clinical Perspective on p 2385
Insulin-like growth factor-1 (IGF-1) is a key regulator of
growth, survival, and differentiation in most cell types,16 and
its importance is demonstrated by the conservation through-
out the evolutionary scale.16 In myocardial biology, IGF-1
and its signal transduction cascade are involved in the control
of virtually every critical biological process, including devel-
opment, cardiomyocyte size and survival, action potential,
and excitation-contraction coupling.17,18 In this report, we
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demonstrate not only that IGF-1 is a target of miR-119 but,
remarkably, that miR-1 expression per se depends on the
activation state of the IGF-1 signal transduction cascade.
Indeed, IGF-1 upregulation correlates with miR-1 depression
and vice versa. Together, these findings unravel a unique
reciprocal molecular circuit between miR-1 and IGF-1.
Methods
Animals
All procedures involving animals were performed in accordance with
institutional guidelines for the care and use of laboratory animals.
Transverse aortic constriction (TAC) experiments were performed
on male C57/Bl6 mice ranging in age from 10 to 12 weeks, with 6
animals per group. AKT transgenic mice with cardiac-specific
overexpression of constitutively active AKT were male mice aged 10
to 12 weeks.
Cell Cultures and Adenoviral Infection
Mouse neonatal cardiomyocytes were prepared as described previ-
ously.11 Mouse C2C12 and 293T cells were obtained from ATCC
(Manassas, Va) and maintained in Dulbecco’s modified Eagle’s
medium (Invitrogen, Carlsbad, Calif) supplemented with 4.5 g/L
glucose, 4 mmol/L L-glutamine, 10% fetal bovine serum, and
penicillin/streptomycin at 37°C in a 5% CO2 atmosphere. C2C12
cells were differentiated in Dulbecco’s modified Eagle’s medium
supplemented with 4% horse serum. MiR-1 and miR-133 adenoviral
vectors (Ad-miR-1 and Ad-miR-133, respectively) as well as the
Ad-Empty control have been described previously.11
Bioinformatics
MiR-1 target prediction was performed with the use of the following
algorithms: miRanda (http://microrna.sanger.ac.uk), TargetScan
(http://www.targetscan.org), and PicTar (http://pic-tar.bio.nyu.edu).
The 3! UTR #G was calculated with the use of the software mFOLD
(http://frontend.bioinfo.rpi.edu/applications/mfold/). MiR-1 pro-
moter analysis was performed with the use of the software MatIn-
spector (http://www.genomatix.de/products/MatInspector).
Figure 1. IGF-1 regulation by miR-1. A, IGF-1 seed sequence
alignment in different species. B, Northern blot analysis for
miR-1 overexpressed by adenovirus (Ad-miR-1) in neonatal car-
diomyocytes. C and D, Western blot analysis and real-time poly-
merase chain reaction for IGF-1 on neonatal cardiomyocytes
infected with adenovirus expressing miR-1, miR-133, and empty
vector (mean$SE, minimum of 3 experiments per group).
GAPDH was used as internal control. E, Luciferase reporter
assay (mean$SE, minimum of 3 experiments per group) on
293T cells, performed by cotransfection of miR-1 oligonucleo-
tide (20 nmol/L) with a luciferase reporter gene linked to wild-
type (wt) or mutated (mt) 3! UTR of IGF-1 (different doses).
*P%0.05 vs control (wt 3! UTR using miR-143).
Figure 2. IGF-1 regulation by miR-1 on skeletal muscle C2C12
cells. A, Western blot analysis for the C2C12 differentiation
markers !-myosin heavy chain (!-MHC) and troponin T. B,
miR-1 expression in C2C12 cells after differentiation into myo-
tubes. Cells were switched to differentiation medium (DM) at day
0. C, Luciferase reporter assay (mean$SE, minimum of 3 exper-
iments per group) on C2C12 cells cultured in growth medium
(GM) and differentiation medium with a luciferase reporter gene
linked to wild-type (wt) or mutated (mt) 3! UTR of IGF-1.
*P%0.05 vs controls (wt 3! UTR in growth medium or mt 3! UTR
in differentiation medium). D, Immunofluorescence staining for
IGF-1 and F-actin of C2C12 cells cultured in growth medium
and differentiation medium for 2 days. E, Quantitative polymer-
ase chain reaction for IGF-1 on C2C12 cells cultured in growth
medium and differentiation medium. GAPDH was used as inter-
nal control.
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Reporter Assays
The miR-1 promoter, which contains 2 potential binding sites for
Foxo3a, was amplified from mouse chromosome 2 with the use of
KOD Taq polymerase (Novagen, San Diego, Calif) and the follow-
ing primers: forward, 5!-CTCTCAGTATCCTAATCCTC-3!; and
reverse, 5!-GTAGGCACTCCTGCGCCGGC-3!. The promoter was
cloned into the reporter plasmid, pGL3.basic (Promega, Madison,
Wis). For the promoter experiment, 293T cells were seeded in
24-well plates (Nunc, Rochester, NY) and infected with adenovi-
ruses (Ad) carrying a dominant negative (DN) or dominant active
(DA) form of AKT20,21 or Foxo3a22 (kindly provided by Dr Do-
menico Accili, Columbia University) and subsequently cotransfected
with the miR-1 promoter-luciferase reporter (100 ng) construct and
the Renilla luciferase plasmid (10 ng) with the use of Lipofectamine
2000 (Invitrogen). For IGF-1 and IGF-1 receptor (IGF-1R) 3! UTR
reporter assays, experiments were performed on human 293T and
murine C2C12 cell lines. The 3! UTR segments of IGF-1 and
IGF-1R 3!UTR mRNAs were subcloned by standard procedures into
psiCHECK-2 (Promega) immediately downstream of the stop codon
of the luciferase gene. MiR-1 seed mutagenesis was performed as
described by the manufacturer (Stratagene, La Jolla, Calif). 293T
cells were transfected with the reporter plasmid (10, 50, and 100 ng)
and miR mimics (20 nmol/L) (Dharmacon, Lafayette, Colo). The
IGF-1 reporter plasmid (50 ng) was transfected into C2C12 cells
with Lipofectamine following a modified manufacturer’s protocol.23
Cells were lysed and assayed for luciferase activity either 24 or 48
hours after transfection. All luciferase assays were performed with
the use of the Dual Luciferase kit (Promega), as described
previously.11,12
Western Blot Analyses
Neonatal cardiomyocytes, C2C12, and 293T cells were collected at
different time points (24, 48 hours) and lysated with the use of RIPA
buffer. The following antibodies were used: IGF-1 (Laboratory
Vision Corporation, Fremont, Calif), !-myosin heavy chain (AB-
cam, Cambridge, Mass), troponin T (Thermo Scientific, Waltham,
Calif), GAPDH (mouse anti-rabbit GAPDH, Cell Signaling, Dan-
vers, Mass), total AKT (Cell Signaling), Ser473 P-AKT (Cell
Signaling), total Foxo3a (Cell Signaling), and Tyr32 P-Foxo3a (Cell
Signaling). Densitometry analyses were performed with the use of
ImageJ (National Institute of Health).
RNA Quantification
For IGF-1 RNA quantification, total RNA was extracted with
the use of the TRIzol reagent (Invitrogen) according to the
manufacturer’s protocol. Complementary DNA was prepared
with the use of SuperScript Reverse Transcriptase cDNA Kit
(Invitrogen). Sybr green quantitative polymerase chain reaction
was performed with the use of the following primers: IGF-1-5!
(5-CACCTCAGACAGGCATTGTG-3); IGF-1-3! (5-TCTGA-
GTCTTGGGCATGTCA-3); GAPDH-5! (5-GACGGCCGCATC-
TTCTTGT-3), GAPDH-3! (5-CACACCGACCTTCACCATTTT-3). For
miRNA quantitative reverse transcription–polymerase chain reac-
tion, total RNA was extracted with the use of TRIzol; primers and
probes specific for human/mouse miR-1 and the internal controls
Sno202 RNA and U6 were purchased from Applied Biosystems.
Amplification and detection were performed with the use of the 7300
Sequence Detection System (ABI), with 40 cycles of denaturation at
Figure 3. Reciprocal regulation of miR-1 and
IGF-1 expression in TAC and AKT overexpression
models of cardiac hypertrophy. A, Northern blot
analysis and relative expression values of miR-1 in
sham-operated and TAC mice (representative
results, mean$SE of a minimum of n&5 mice per
group). B, Western blot analysis for IGF-1 in left
ventricles from sham- and TAC-operated mice
(representative results, mean$SE of a minimum of
n&5 mice per group). Band intensities were quan-
tified with the use of ImageJ software version 1.34
(http://rsb.info.nih.gov/ij/) and normalized to
GAPDH. C, miR-1 quantitative real-time polymer-
ase chain reaction on AKT and wild-type (WT)
mice. D, Western blot analysis for IGF-1 expres-
sion on AKT and wild-type mice (representative
results, mean$SE of a minimum of n&5 mice per
group). *P%0.05 vs controls (sham or WT).
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95°C (15 seconds) and annealing/extension at 60°C (60 seconds).
For the miRNA quantification, this was preceded by reverse tran-
scription at 42°C for 30 minutes and denaturation at 85°C for 5
minutes.
Northern blotting was performed to confirm the expression levels
of miR-1. Probes and anti-sense oligonucleotides against mature
miR-1 and U6 were locked nucleic acid based (Exiqon, Vedbaek,
Denmark). Densitometry analyses were performed with the use of
ImageJ (National Institutes of Health).
Immunofluorescence
C2C12 myoblasts were plated in Laboratory-Tek 2-well chamber
slides (2.105 cells per well). IGF-1 staining was performed with the
use of primary antibody (Laboratory Vision Corporation) together
with Alexa Fluor 594 phalloidin (Molecular Probes, Carlsbad, Calif),
diluted in 5% BSA/0.1% Triton X-100/PBS. Goat anti-rabbit anti-
body conjugated to Alexa Fluor 488 (Molecular Probes) was used as
secondary antibody.
Myocardial Biopsies
Eight patients (6 male, 2 female; mean age, 46.8$13.6 years) with
acromegaly were evaluated with noninvasive (ECG, 2-dimensional
echocardiography) and invasive cardiac studies (cardiac catheterization,
coronary and left ventricular angiography, and left ventricular endo-
myocardial biopsy) before neurosurgery and/or somatostatin ana-
logue therapy. All invasive studies were performed after informed
consent was obtained and with the approval of the ethics committee
of the Department of Cardiovascular and Respiratory Science,
University La Sapienza, Rome, Italy. Endomyocardial biopsies were
drawn, stored, and processed as described previously.24
Statistical Analysis
Statistical and frequency distribution analysis was performed by
GraphPad Prism 4.0 (GraphPad Software, Inc, La Jolla, Calif). Data
in Figure 1 were analyzed with the use of a 2-way ANOVA adjusted
pairwise test. Data in Figures 2 and 3 were analyzed with 2-way
ANOVA adjusted for multiple comparisons and 1-way ANOVA,
respectively. Data in Figures 4 and 5 were analyzed with 2-way
ANOVA adjusted for multiple comparisons. Data in Figure 6 and
Figure I in the online-only Data Supplement were analyzed with
1-way ANOVA and 2-way ANOVA adjusted for multiple compar-
isons, respectively. The linear correlation on acromegaly patient
parameters was calculated with the Pearson product moment corre-
lation coefficient. A value of P%0.05 was considered to be statisti-
cally significant.
Results
Bioinformatics
The identification of true miR target genes is a great
challenge, and computational algorithms have been the
major driving force in predicting miR targets to date.25–27
In the present study, we used the following target pre-
diction algorithms: miRanda (http://microrna.sanger.ac.
uk),28 TargetScan (http://www.targetscan.org),29 and Pic-
Tar (http://pic-tar.bio.nyu.edu).5,30 These approaches are
based on the identification of elements in the 3! UTR of target
genes complementary to the seed sequence of the miR of
interest, calculation of thermodynamic properties of 3! UTRs,
and phylogenetic conservation of complementary sequences
in the 3! UTRs of orthologous genes. To reduce the number
of false-positive targets, we also analyzed mRNA secondary
structure flanking the seed sequence. In fact, several lines of
evidence have shown that complex mRNA tertiary structures
might prevent miR/mRNA interactions that limit the number
of single-stranded regions accessible for binding to miRs.10,13
Using this approach, we identified several putative targets of
cardiac relevance, including, as shown recently, IGF-1.19 Its
3! UTR contains only 1 seed sequence, which has a #G
energy value of '4.5 and '11.9 kcal/mol for mRNA
sequences 5! and 3! of the seed sequence, respectively.
Interestingly, this sequence is evolutionally conserved be-
tween species (Figure 1A). Another putative target included
IGF-1R, which is involved in the IGF-1 pathway (Figure IA
in the online-only Data Supplement). IGF-1R belongs to the
large class of tyrosine kinase transmembrane receptors and is
directly activated by IGF-1 as well as the related growth
factor IGF-2.31 The #G energy values of the 5! and 3! RNA
sequences around their seed sequences are '18 and '14
kcal/mol for IGF-1R.
Figure 4. Regulation of miR-1 by the IGF-1 path-
way. A, miR-1 quantitative real-time polymerase
chain reaction on neonatal cardiomyocytes treated
with 10 nmol/L IGF-1 at different time points. NT
indicates neonatal cardiomyocytes not treated.
Sno202 RNA was utilized as internal control. B,
miR-1 quantitative real-time polymerase chain reac-
tion on differentiated C2C12 cells treated with vari-
ous doses of IGF-1 for 2 days. GM indicates C2C12
kept in growth medium and not treated; DM NT,
C2C12 differentiated not treated; and DM, C2C12
differentiated. Sno202 RNA was utilized as internal
control. C, miR-1 quantitative real-time polymerase
chain reaction on neonatal cardiomyocytes infected
with Ad-DA-AKT and Ad-DN-AKT at different multi-
plicity of infection (m.o.i) values (Ad-Empty m.o.i 100;
Ad-Empty m.o.i 90(Ad-AKT [DA or DN] m.o.i. 10;
Ad-Empty m.o.i 50(Ad-AKT [DA or DN] m.o.i. 50;
Ad-AKT [DA or DN] m.o.i. 100). Sno202 RNA was
utilized as internal control. *P%0.05 vs controls (neo-
natal cardiomyocytes NT, C2C12 DM NT, and
Ad-Empty). Data are expressed as the mean$SE of
3 independent experiments.
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IGF-1 Is a Target of miR-1 in Cardiac Myocytes
In neonatal cardiomyocytes, overexpression of miR-1 but not
its physiologically coexpressed miR-133 resulted in a signif-
icant decrease in IGF-1 protein levels (Figure 1B and 1C)
without affecting its mRNA levels (Figure 1D). To confirm
IGF-1 as a real miR-1 target, the wild-type 3! UTR of IGF-1
was cloned downstream of the luciferase gene and assayed in
293T cells, which do not express endogenous miR-1 (data not
shown). When cotransfected with miR-1 mimics, the assay
resulted in a significant decrease ()45%) in luciferase
activity (Figure 1E). In contrast, no effect was observed when
an unrelated miR (miR-143) with no complementarity to any
seed sequence in the 3! UTR of IGF-1 was used (Figure 1E).
Consistent with these data, cotransfection of miR-1 with
constructs containing mutated 3! UTR seed sequences did not
result in any decrease in luciferase activity (Figure 1E).
Similar results were obtained for luciferase constructs con-
taining 3! UTRs of IGF-1R, in which cotransfection with
miR-1 mimics resulted in a significant decrease in luciferase
activity (Figure IB in the online-only Data Supplement).
Consistent downregulation of IGF-1R protein level was
found in differentiated C2C12 cells (Figure IC in the online-
only Data Supplement).
Reciprocal Regulation of miR-1 and IGF-1 During
C2C12 Skeletal Muscle Cell Differentiation
It is well established that IGF-1 regulates skeletal muscle cell
differentiation32 and that the miR-1 level changes during
development in skeletal muscle cells.12 In the present study,
we used C2C12 cells as an in vitro cell model that recapitu-
lates skeletal muscle differentiation. On serum withdrawal,
C2C12 myoblasts stop proliferating, irreversibly exit from the
cell cycle, differentiate, and fuse into multinucleated skeletal
myotubes after the concomitant coexpression of muscle
differentiation markers.33 Consistent with that, upregulation
of cell differentiation markers 2 days after serum withdrawal
confirmed C2C12 differentiation (Figure 2A). Precursor and
mature miR-1 levels, although absent at the myoblast stage,
were remarkably increased at day 2 of differentiation (Figure
2B), confirming previous observations.12 The expression of
miR-1 increased significantly after the switch to differentia-
tion conditions and remained at a high level up to day 10,
when myotube formation was completed and contractile
activity could be observed (data not shown).
To monitor changes in the miR-1 level on C2C12 differ-
entiation, we performed a luciferase assay by transfecting the
IGF-1 luciferase construct in proliferating and differentiating
C2C12 cells. Results show a significant reduction ()35%) in
luciferase expression in differentiated cells compared with
mutant IGF-1 3! UTR vector and with myoblast state (Figure
2C), indicating that inhibition of the reporter gene was a
consequence of the increased endogenous level of miR-1. No
changes were obtained when a luciferase reporter not carry-
ing any 3! UTR was transfected (data not shown). In addition,
immunofluorescence staining of C2C12 cells kept in differ-
entiation medium demonstrated a striking decrease in the
IGF-1 protein level starting from day 2 of differentiation
(Figure 2D). In contrast, the IGF-1 mRNA level was unal-
tered (Figure 2E).
Reciprocal Regulation of miR-1 and IGF-1
Expression in the TAC and AKT Overexpression
Mouse Models of Cardiac Hypertrophy
We11 and others15 have previously shown an inverse correla-
tion between miR-1 expression and cardiac hypertrophy. We
thus hypothesized that repression of miR-1 in the TAC model
(Table I in the online-only Data Supplement) would be
accompanied by an increase in the IGF-1 protein level. In
agreement with this, Western blot analysis demonstrated an
increased IGF-1 protein level after TAC, together with a
decreased miR-1 level (Figure 3A and 3B). Similarly, a
reduction in miR-1 expression was found in another mouse
Figure 5. Foxo3a regulates miR-1 expression. A, The 2 potential
Foxo3a binding sites on miR-1 promoter are indicated as BS1
and BS2. Both fragments of the miR-1 promoter were synthe-
sized and linked to the luciferase (Luc) reporter gene. B, 293T
cells were infected with Ad-Empty or Ad-DA-foxo and Ad-DN-
foxo at a multiplicity of infection (m.o.i.) of 50. Twenty-four
hours after infection, cells were transfected with empty vector
(pGL3.basic) or miR-1 promoter constructs, respectively. Firefly
luciferase activities were normalized to Renilla luciferase activi-
ties. C, Neonatal cardiomyocytes were infected with Ad-DA-foxo
and DN-foxo at different m.o.i (Ad-Empty m.o.i 50; Ad-Empty
m.o.i 49(Ad-foxo [DA or DN] m.o.i. 1; Ad-Empty m.o.i 40(Ad-
foxo [DA or DN] m.o.i. 10; Ad-foxo [DA or DN] m.o.i. 50). Cells
were harvested 48 hours after infection and analyzed for miR-1
levels by quantitative real-time polymerase chain reaction.
Sno202 RNA was utilized as internal control. D, Western blot on
C2C12 (DM1 and DM3 indicate differentiation medium at days 1
and 3, respectively) (left) and neonatal cardiomyocytes infected
with Ad-miR-1 (m.o.i. 100) (right) for total AKT, P-AKT, total
Foxo3a, and P-Foxo3a. Band intensities were quantified (bottom
of each panel) as described in Figure 3. MHC indicates myosin
heavy chain. *P%0.05 vs controls (Ad-Empty, Ad-DN-foxo). Data
are expressed as the mean$SE of 3 independent experiments.
Elia et al miR-1 and IGF-1 Circuitry in Cardiac Muscle 2381
 at CONS CALIFORNIA DIG LIB on December 9, 2009 circ.ahajournals.orgDownloaded from 
model of cardiac hypertrophy, in which the downstream
target of IGF-1, AKT, is constitutively overexpressed.20
Consistent with our observations, decreased miR-1 expres-
sion was accompanied by an increased IGF-1 protein level
(Figure 3C and 3D).
The IGF-1 Pathway Controls miR-1 Levels
Through Foxo3a Transcriptional Regulation
Molecular circuits in which miRs control the level of a factor
that in turn regulates the same miRs have been described. For
instance, Fontana and al34 described a circuitry involving
sequentially miR-17-5p-20a-106a and AML1, in which miR-
17-5p-20a-106a functions as a master gene complex inter-
linked with AML1 in a mutual negative feedback loop. We
hypothesized that a circuit between miR-1 and IGF-1 might
exist in striated muscle. To test this assumption, we measured
miR-1 levels in different in vitro cell models in which IGF-1
activity was either diminished or increased. In neonatal
cardiomyocytes treated with IGF-1, miR-1 expression was
significantly decreased starting from 3 hours after treatment
and remained depressed until 6 hours after treatment (Figure
4A). Notably, in C2C12 differentiated cells in which miR-1 is
highly expressed, treatment with increasing IGF-1 doses
induced a concomitant decrease in miR-1 expression with a
significant reduction at a dose of 100 nmol/L IGF-1 (Figure
4B). A similar downregulation in miR-1 levels was observed
when neonatal cardiomyocytes were infected with an adeno-
virus carrying a dominant active form of AKT (DA-AKT)20
but not a dominant negative mutant (DN-AKT) (Figure 4C).
To study miR-transcriptional regulation, we analyzed the
promoter region of miR-1 and identified 2 potential binding
sites for Foxo3a, a transcription factor with cellular localiza-
tion and transcriptional activity depending on its phosphory-
lation status, which in turn is regulated by AKT (Figure 5A).
The miR-1 level was measured in neonatal cardiomyocytes
infected with adenovirus carrying a dominant active (DA-
foxo) or dominant negative form (DN-foxo) of Foxo3a. In
DA-foxo, all 3 potential AKT phosphorylation sites have
been replaced by nonphosphorylatable amino acids, prevent-
ing it from being excluded from the nucleus in response to
insulin, making it constitutively active.22 In DN-foxo, the
transactivation domain (#256), which is important for coac-
tivator recruitment, has been deleted. Our results demonstrate
that although DA-foxo could upregulate miR-1 levels, the
DN-foxo mutant could not (Figure 5C). These data strongly
suggest that Foxo3a is able to influence miR-1 expression
levels. Moreover, to test whether Foxo3a can regulate miR-1
promoter activity, we cloned a fragment containing the 2
potential binding sites mapped on mouse chromosome 2 into
the luciferase vector. As shown in Figure 5B, DA-foxo, but
not DN-foxo, induced a marked elevation of miR-1 promoter
activity.
miR-1 overexpression should induce a decrease in the
phosphorylation state of AKT and Foxo3 because of the
decreased levels of IGF-1 and IGF-1R and thus a generalized
decrease of IGF-1 signal transduction pathway. We therefore
determined phospho-Foxo3a and phospho-AKT in differen-
tiated C2C12 and neonatal cardiomyocytes infected with
Ad-miR-1; data show a significant downregulation of both
phospho-Foxo3a and phospho-AKT (Figure 5D). Taken to-
gether, these data suggest that Foxo3a can transcriptionally
regulate miR-1 expression.
Repression of miR-1 Levels and Correlation With
Cardiac Hypertrophy in Acromegalic Patients
Acromegaly is a syndrome that results from overproduction
of growth hormone, which in turn increases IGF-1 synthesis
in peripheral tissues and leads to a significant elevation in the
IGF-1 plasma level.35 Cardiac hypertrophy is a dangerous
consequence of growth hormone overproduction, and echo-
Figure 6. miR-1 expression in acromegalic
patients. A, Left ventricular biopsy (A) from a
patient with acromegalic cardiomyopathy showing
remarkable cardiomyocyte hypertrophy compared
with normal control (B) (hematoxylin-eosin staining;
magnification *250). B, miR-1 quantitative real-
time polymerase chain reaction on heart biopsies
from acromegaly patients compared with healthy
donors. U6 RNA was utilized as internal control.
C, Pearson product moment linear correlation
between the left ventricular (LV) mass index, maxi-
mal wall thickness (MWT), and level of miR-1 in
acromegaly patients. *P%0.05 vs control (healthy
donors). Data are expressed as the mean$SE of 3
independent experiments.
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cardiographic analysis of cardiac function in patients with
acromegaly consistently showed significantly increased left
ventricular mass as well as end-diastolic left ventricular wall
and septum thickness (Table).36 Furthermore, histological
examination of myocardial biopsies showed hypertrophied
cardiomyocytes with interstitial, perivascular, and focal re-
placement fibrosis (Figure 6A). Because blood levels of
IGF-1 are elevated in patients with acromegaly, we measured
miR-1 levels in myocardial biopsies by quantitative reverse
transcription–polymerase chain reaction (Figure 6B). Inter-
estingly, all patients showed a significant reduction in cardiac
miR-1 levels compared with healthy donors, and there was a
linear inverse correlation between miR-1 levels and left
ventricular mass and end-diastolic left ventricular wall thick-
ness (Figure 6C).
Discussion
MiR-mediated posttranscriptional gene regulation is now
considered a fundamental player of many genetic programs.
However, despite our ability to identify miRs, few regulatory
targets have been established for vertebrate miRs. In this
study, we demonstrated the potential feedback loop in which
miR-1 and its target IGF-1 are reciprocally regulated.
Binding of IGF-1 to its receptor activates its intrinsic
receptor tyrosine kinase, which phosphorylates several intra-
cellular substrates such as the insulin receptor substrate-1 and
Shc,37,38 leading to the activation of signaling pathways,
including phosphatidylinositol 3-kinase/AKT pathways.39
Active AKT in turn phosphorylates and inhibits the winged-
helix family of transcription factors, Foxo3a. In the present
study, we demonstrated not only through IGF-1 stimulation
but also with transfection of AKT or its downstream tran-
scription factor Foxo3a that the IGF-1 pathway controls
miR-1 expression (Figure 7). In fact, overexpression of AKT
in neonatal cardiomyocytes reduces miR-1 expression,
whereas overexpression of Foxo3a increases the miR level.
These data are further supported by the identification of
IGF-1R31 as a miR-1 target.
Several miR-1 cardiac targets involved in the control of
hypertrophy, cell cycle, excitation-contraction coupling, and
membrane excitability have been identified, including
HDAC4,12 Hand2,13 the K( channel subunit, Kir2.1 (KCNJ2),
connexin 43 (GJA1),14 Ras GTPase–activating protein (Ras-
GAP), cyclin-dependent kinase 9 (Cdk9), fibronectin, Ras
homolog enriched in brain (Rheb),15 and, as recently shown,
IGF-1.19 This indicates that miR-1 is involved in many
different biological processes.
The importance of the IGF-1 pathway in cardiac function is
well established.40 Indeed, the effects of IGF-1 on adult
muscle are pleiotropic, ranging from antiapoptotic,18,41–43
hypertrophic, and regenerative effects on cardiac mus-
cle.31,44,45 Thus, both miR-1 and IGF-1 are involved in most
biological processes controlling cardiac function. Notably,
our results strongly indicate miR-1 as a modifier and a
regulator of the multiple effects of IGF-1 in cardiac muscle.
The possibility that IGF-1 is a target of miR-1 has been
suggested previously.19,46 However, we show here the bio-
logical relevance of this functional interaction and demon-
strate that it is part of the autoregulatory circuit in cardiac and
skeletal muscle (Figure 7). Our results also indicate that
miR-1 may simultaneously downregulate IGF-1R together
with IGF-1 protein, leading to a significant downmodulation
of the whole downstream signal transduction cascade. The
importance of our observation is strengthened by data from
human samples, which strongly indicate the involvement of
the miR-1 and IGF-1 regulatory loop in controlling human
Figure 7. Proposed model of the miR-1/IGF-1 regulatory loop.
RE indicates responsive element.
Table. Clinical and Echocardiographic Characteristics of Acromegalic Patients
Patients
Variables 1 2 3 4 5 6 7 8
Age, y 37 30 49 31 69 55 57 47
Sex M M M F F M M M
Body surface area, g/m2 1.95 1.99 2.03 2.27 1.68 2.11 2.10 2.11
Presumed disease duration, y 7 2 4 4 10 1 2 4
IGF-1 at biopsy, ng/mL* 1241 1205 634 952 657 938 938 787
LV ejection fraction, % 54 58 56 60 50 50 52 55
Maximal wall thickness, mm 14 13 10 11 13 14 16 13
LV mass index, g/m2† 151 132 88 103 143 132 160 136
LV indicates left ventricular.
*Normal range&80-330 ng/mL.
†LV mass index calculated according to Devereux and Reichek36; normal values&91$20 g/m2.
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cardiac hypertrophy. Indeed, the striking inverse correlation
between miR-1 levels and the degree of cardiac hypertrophy
indicates that miR-1 is a key player in this process in humans.
The interplay between IGF-I, AKT, Foxo3a, and miR-1 may
provide a new paradigm to understand the manner in which
IGF-1 modulates cardiac and skeletal muscle structure and
function.18,47
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CLINICAL PERSPECTIVE
MicroRNAs (miRNAs/miRs) are small conserved RNA molecules of 22 nucleotides that negatively modulate gene
expression primarily through base paring to the 3! untranslated region of target messenger RNAs. The muscle-specific
miR-1 has been implicated in cardiac hypertrophy, heart development, cardiac stem cell differentiation, and arrhythmias
through targeting of regulatory proteins. In this study, we investigated the molecular mechanisms through which miR-1
intervenes in regulation of cardiac and skeletal muscle cell growth and differentiation. We demonstrate that miR-1 controls
the expression of insulin-like growth factor-1 (IGF-1) and IGF-1 receptor protein levels by translation. The IGF-1 pathway
is critically involved in many aspects of cardiac development and cardiac function. We found that in conditions in which
miR-1 is decreased, such as cardiac hypertrophy, IGF-1 is increased; the regulation is reciprocal because IGF-1 stimulation
leads to downregulation of miR-1 levels. This effect is dependent on IGF-1 inhibition of the Foxo3 transcription factor,
which regulates miR-1 promoter activity. The clinical relevance of these observations is demonstrated by analyzing the
expression of miR-1 in cardiac biopsies of patients with acromegaly, a condition in which growth hormone and IGF-1 are
overproduced and cardiac myocyte size is dramatically increased; miR-1 levels inversely correlate with echocardiographic
parameters of cardiac mass in these patients. Our results add information in regard to the manner in which the IGF-1
pathway regulates cardiac function, demonstrating the role of miR-1 in response to cardiac stress and hypertrophy.
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